Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Blood (2023) 142 (Supplement 1): 4641.

https://doi.org/10.1182/blood-2023-181595

Published: 2023

Journal Articles

Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53

Therese Aurran-Schleinitz, Cécile Tomowiak, Damien Roos-Weil, Emmanuelle Ferrant, Béatrice Mahé, Lysiane Molina, Loic Ysebaert, Luc Mathieu Fornecker, Anne-Sophie Michallet, Vincent Levy, Romain Guieze, Alain Delmer

Blood (2022) 140 (Supplement 1): 7030–7031.

https://doi.org/10.1182/blood-2022-163096

Published: 2022

Journal Articles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Blood (2022) 140 (Supplement 1): 7013–7015.

https://doi.org/10.1182/blood-2022-157963

Published: 2022

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Blood (2022) 140 (Supplement 1): 7007–7009.

https://doi.org/10.1182/blood-2022-159678

Published: 2022

Journal Articles

Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Blood (2022) 140 (Supplement 1): 6631–6632.

https://doi.org/10.1182/blood-2022-159695

Published: 2022

Journal Articles

Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia

Anne Wanquet, Rudy Birsen, Richard Lemal, Mathilde Hunault, Véronique Leblond, Thérèse Aurran-Schleinitz

Blood (2016) 127 (19): 2356–2358.

https://doi.org/10.1182/blood-2016-02-697193

Published: 2016

Journal Articles

First Line Chronic Lymphocytic Leukemia Immunochemotherapy for the Elderly Patients over 79 Years Is Feasible, and Achieves Good Results: A Filo Retrospective Study

Blood (2015) 126 (23): 4170.

https://doi.org/10.1182/blood.V126.23.4170.4170

Published: 2015

Journal Articles

Central Nervous System Involvement in Chronic Lymphocytic Leukemia: Diagnosis and Treatment in a Retrospective Cohort of Thirty Patients

Blood (2015) 126 (23): 2948.

https://doi.org/10.1182/blood.V126.23.2948.2948

Published: 2015

Journal Articles

Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial

Blood (2014) 124 (21): 3341.

https://doi.org/10.1182/blood.V124.21.3341.3341

Published: 2014

Journal Articles

Role Of Allogeneic Transplant In Poor Risk CLL Patients: A Long-Term Monocentric Experience In 39 Patients

Therese Aurran-Schleinitz, MD, Anne Wanquet, Sabine Furst, MD, Benjamin Esterni, Ph.D., Reda Bouabdallah, MD, Diane Coso, MD, Christine Arnoulet, Pharm. D., Jean El Cheikh, MD, Catherine Faucher, MD, Luca Castagna, MD, Christian Chabannon, MD, PhD, Didier Blaise

Blood (2013) 122 (21): 5531.

https://doi.org/10.1182/blood.V122.21.5531.5531

Published: 2013

Journal Articles

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Andreas Bühler, Clemens Wendtner, MD, Michael Hallek, Thomas J. Kipps, MD, PhD, Laura Rassenti, PhD, Graeme Fraser, Anne-Sophie Michallet, Peter Hillmen, Jan Duerig, MD, Stephanie A. Gregory, Matt Kalaycio, MD, Therese Aurran-Schleinitz, Livio Trentin, Brendan Purse, Jennie Zhang, Jay Mei, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 1638.

https://doi.org/10.1182/blood.V122.21.1638.1638

Published: 2013

Journal Articles

Salvage Therapies in Patients with High-Risk Relapse After Fludarabine, Cyclophosphamide, Rituximab (FCR) for Chronic Lymphocytic Leukemia: The French CLL Intergroup Experience

Luc-Matthieu Fornecker, MD, Therese Aurran-Schleinitz, Anne-Sophie Michallet, MD, PhD, Bruno Cazin, MD, Jehan Dupuis, MD, Romain Guieze, MD, Marie-Sarah Dilhuydy, MD, Jean-Marc Zini, MD, PhD, Cécile Tomowiak, MD, Stéphane Leprêtre, MD, Florence Cymbalista, MD, PhD, Annie Brion, MD, Pierre Feugier, MD, PhD, Veronique Leblond, Loic Ysebaert, MD PhD

Blood (2012) 120 (21): 1796.

https://doi.org/10.1182/blood.V120.21.1796.1796

Published: 2012

Journal Articles

Potential Synergic Effect of Lenalidomide-Rituximab Combination: Durable Complete Remissions in Refractory Diffuse Large B Cell Lymphoma

Vadim Ivanov, MD, PhD, Diane Coso, MD, Therese Aurran-Schleinitz, MD, Jean-Marc Schiano de Colella, MD, Anne-Marie Stoppa, MD, Jerome Rey, MD, Florence Broussais, MD, Didier Blaise, MD, Reda Bouabdallah, MD

Blood (2011) 118 (21): 4989.

https://doi.org/10.1182/blood.V118.21.4989.4989

Published: 2011

Journal Articles

Frontline High Dose Chemotherapy Supported by Autologous PBSCT Might Improve Survival In Elderly Patients (≥60 Years) with High Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Vadim Ivanov, MD, Diane Coso, MD, Jerome Rey, MD, Therese Aurran-Schleinitz, MD, Anne-Marie Stoppa, MD, Jean-Marc Schiano de Colella, MD, Didier Blaise, MD, Reda Bouabdallah, MD

Blood (2010) 116 (21): 5190.

https://doi.org/10.1182/blood.V116.21.5190.5190

Published: 2010

NARROW

Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia

First Line Chronic Lymphocytic Leukemia Immunochemotherapy for the Elderly Patients over 79 Years Is Feasible, and Achieves Good Results: A Filo Retrospective Study

Central Nervous System Involvement in Chronic Lymphocytic Leukemia: Diagnosis and Treatment in a Retrospective Cohort of Thirty Patients

Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial

Role Of Allogeneic Transplant In Poor Risk CLL Patients: A Long-Term Monocentric Experience In 39 Patients

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Salvage Therapies in Patients with High-Risk Relapse After Fludarabine, Cyclophosphamide, Rituximab (FCR) for Chronic Lymphocytic Leukemia: The French CLL Intergroup Experience

Potential Synergic Effect of Lenalidomide-Rituximab Combination: Durable Complete Remissions in Refractory Diffuse Large B Cell Lymphoma

Frontline High Dose Chemotherapy Supported by Autologous PBSCT Might Improve Survival In Elderly Patients (≥60 Years) with High Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only